Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.44 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.42 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | DPP4 | P27487 | 2/20 | 0.41 |
| ▸ | F2 | P00734 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MIF | P14174 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11072368 | 0.86 | ESR1 (0.50) | ADRA2AADRA2CCYP2D6LMNAALDH1A1 | |
| SCHEMBL19151931 | 0.85 | PTGS2 (0.52) | ALDH1A1 | |
| SCHEMBL908216 | 0.84 | TAAR1 (0.50) | TAAR1ADRA2AADRA2CCYP2D6LMNA | |
| SCHEMBL10628918 | 0.79 | CYP2C19 (0.39) | CYP2D6LMNAKDM4ETSHRALDH1A1 | |
| SCHEMBL22694355 | 0.79 | ALDH1A1 (0.41) | CYP2D6KDM4EALDH1A1 | |
| SCHEMBL599878 | 0.79 | TAAR1 (0.48) | TAAR1ADRA2AADRA2CCYP2D6LMNA | |
| SCHEMBL15586 | 0.79 | TAAR1 (0.48) | TAAR1ADRA2AADRA2CCYP2D6LMNA | |
| SCHEMBL19519886 | 0.79 | TAAR1 (0.48) | TAAR1ADRA2AADRA2CCYP2D6LMNA | |
| SCHEMBL448348 | 0.77 | DPP4 (0.53) | TAAR1CYP2D6LMNADPP4F2 | |
| SCHEMBL2844548 | 0.77 | TAAR1 (0.44) | TAAR1ADRA2AADRA2CCYP2D6LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12570774-B2 | Cycloolefin resin cured product having oxygen barrier properties | RIMTEC CORPORATION (JP) | 2026-03-10 | — | — | US | disclosed |
| EP-4703402-A1 | POLYMERIZABLE COMPOSITION AND MOLDED ARTICLE | RIMTEC Corporation (JP) | 2026-03-04 | — | — | EP | disclosed |
| EP-3960414-B1 | METHOD FOR PRODUCING CYCLOOLEFIN RESIN-DECORATIVE MOLDED ARTICLE | RIMTEC CORP (JP) | 2025-08-06 | — | — | EP | disclosed |
| US-12343905-B2 | Method for producing cycloolefin resin-decorative molded article | RIMTEC CORPORATION (JP) | 2025-07-01 | — | — | US | disclosed |
| WO-2024224997-A1 | POLYMERIZABLE COMPOSITION AND MOLDED ARTICLE | RIMTEC株式会社 | 2024-10-31 | — | — | WO | disclosed |
| US-20240287234-A1 | COMPOSITE MATERIAL AND MOLDED COMPOSITE MATERIAL | RIMTEC CORPORATION (JP) | 2024-08-29 | — | — | US | disclosed |
| US-12012474-B2 | Composite material and molded composite material | RIMTEC CORPORATION (JP) | 2024-06-18 | — | — | US | disclosed |
| US-20240002585-A1 | CYCLOOLEFIN RESIN CURED PRODUCT | RIMTEC CORPORATION (JP) | 2024-01-04 | — | — | US | disclosed |
| US-20230322978-A1 | CYCLOOLEFIN RESIN CURED PRODUCT HAVING OXYGEN BARRIER PROPERTIES | RIMTEC CORPORATION (JP) | 2023-10-12 | — | — | US | disclosed |
| US-11710590-B2 | Superconducting coil device and method for producing same | RAILWAY TECHNICAL RESEARCH INSTITUTE (JP) | 2023-07-25 | — | — | US | disclosed |
| CN-101568567-A | Polymerizable composition | ZEON CORP (JP) | 2009-10-28 | — | — | CN | disclosed |
| EP-2098550-A1 | POLYMERIZABLE COMPOSITION | ZEON CORPORATION (JP) | 2009-09-09 | — | — | EP | disclosed |
| CN-101528803-A | Polymerizable composition, crosslinkable resin, and method for producing and use thereof | ZEON CORP (JP) | 2009-09-09 | — | — | CN | disclosed |
| CN-101528804-A | Polymerizable composition, crosslinkable resin, process for producing the same, and use | ZEON CORP (JP) | 2009-09-09 | — | — | CN | disclosed |
| CN-101522765-A | Molded object, process for producing the same, and crosslinked molding and copper-clad laminate each obtained from the same | ZEON CORP (JP) | 2009-09-02 | — | — | CN | disclosed |
| EP-2083032-A1 | POLYMERIZABLE COMPOSITION, CROSSLINKABLE RESIN, PROCESS FOR PRODUCTION THEREOF, AND USE THEREOF | ZEON CORPORATION (JP) | 2009-07-29 | — | — | EP | disclosed |
| EP-2077289-A1 | POLYMERIZABLE COMPOSITION, CROSSLINKABLE RESIN, PROCESS FOR PRODUCING THE SAME, AND USE | ZEON CORPORATION (JP) | 2009-07-08 | — | — | EP | disclosed |
| EP-2067812-A1 | MOLDED OBJECT, PROCESS FOR PRODUCING THE SAME, AND CROSSLINKED MOLDING AND COPPER-CLAD LAMINATE EACH OBTAINED FROM THE SAME | ZEON CORPORATION (JP) | 2009-06-10 | — | — | EP | disclosed |
| US-4806685-A | EXERTS VARIOUS EFFECTS ON ENDOCRINOUS SYSTEM OF RATS; INHIBITS GROWTH OF MAMMARY TUMORS | GYOGYSZERKUTATO INTEEZET/PHARMACEUTICAL RESEARCH INSTITUTE (HU) | 1989-02-21 | — | — | US | disclosed |
| US-4806685-A | EXERTS VARIOUS EFFECTS ON ENDOCRINOUS SYSTEM OF RATS; INHIBITS GROWTH OF MAMMARY TUMORS | GYOGYSZERKUTATO INTEEZET/PHARMACEUTICAL RESEARCH INSTITUTE (HU) | 1989-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11710590-B2 | Superconducting coil device and method for producing same | COIL, NBAS, NUP50 | TAAR1 838/4885ADRA2A 2848/4885ADRA2C 3801/4885 |
| US-12570774-B2 | Cycloolefin resin cured product having oxygen barrier properties | HMOX1, GPX1, ALOX12 | TAAR1 2331/4885ADRA2A 1764/4885ADRA2C 2741/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.